Regenity Biosciences earned FDA 510(k) clearance for RejuvaKnee, a collagen-based meniscus implant designed for reinforcement and repair of soft tissue injuries of the meniscus, the company said Oct. 8.
The implant helps native meniscal tissue regenerate instead of needing to cut or replace it, according to a news release. An animal study also found that RejuvaKnee could withstand full weight bearing, and the knee returned to full range of motion after three months of implantation.
RejuvaKnee is the 60th FDA-cleared product from Regenity Biosciences.